Arecor Therapeutics
plc
("Arecor", the "Company" or the "Group")
ARECOR ANNOUNCES LAUNCH OF
OGLUO® IN THE
NETHERLANDS
-
Launch builds on
continued pan-European commercial roll-out following earlier
launches in Denmark, Norway, Austria, Germany and the
UK
Cambridge, UK,
29 February 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, notes the announcement today from
subsidiary company, Tetris Pharma Ltd, that Ogluo® (glucagon
prefilled autoinjector pen) has been launched in the Netherlands as
a treatment for severe hypoglycaemia in adults, adolescents, and
children aged two years and over living with diabetes
mellitus.
Ogluo® has been launched in the Netherlands by
Goodlife, under the previously announced, existing
commercialisation agreement between Tetris Pharma Ltd and Goodlife,
which has established Goodlife as the sole partner for the import,
marketing and distribution of the product in the BeNeLux
region.
See full Tetris Pharma announcement
below:
Ogluo® launches in the
Netherlands
Availability of glucagon prefilled
autoinjector pen in first BeNeLux country, in partnership with
Goodlife, further expands reach of Ogluo® across
Europe
Continued momentum in pan European
roll-out following earlier launches in Denmark, Norway, Austria,
Germany and the UK
29 February 2024 - Tetris Pharma Ltd ("Tetris
Pharma" or "the Company"), a subsidiary of biopharmaceutical
company, Arecor Therapeutics plc (AIM: AREC), today announces the
launch of Ogluo® (glucagon prefilled autoinjector pen) in the
Netherlands as a treatment for severe hypoglycaemia in adults,
adolescents, and children aged two years and over living with
diabetes mellitus.
The launch is part of an existing exclusive
commercialisation agreement between Tetris Pharma Ltd and Goodlife,
announced in September 2023, which established Goodlife as the sole
partner for the import, marketing and distribution of the product
in the BeNeLux region.
Ogluo® is a ready-to-use, ambiently stored,
preparation of glucagon in an auto-injector for patients within the
licenced indication living with diabetes suffering from severe
hypoglycaemia. Today's launch builds on the continued roll-out of
Ogluo® across key European markets, including, Denmark, Norway,
Austria, Germany and the UK, as part of Tetris Pharma's
pan-European commercialisation programme.
Dr. Helen
Parris, Senior Vice President, Commercial and General Manager of
Tetris Pharma, commented: "The launch of Ogluo®
in the Netherlands presents a significant milestone for Tetris
Pharma, strengthening the commercial reach and pan-European
presence of this important product and giving patients living with
diabetes who may experience severe hypoglycaemia, a treatment
option to tackle those events. Goodlife's leading know-how and
expertise of regional market dynamics make them an ideal partner to
support with the roll-out of Ogluo® in the BeNeLux region.
We look forward to continuing to expand our reach within
Europe to bring this treatment option to people living with
diabetes."
Notes to
Editors
Tetris Pharma, a subsidiary of Arecor
Therapeutics plc, is a commercial-stage specialty pharmaceutical
company with expertise in registering, marketing, sales and the
distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and
growing sales. Having secured distribution rights for already
licensed products across Europe, we have a portfolio of niche
injectable products including Ogluo®, a ready-to-use glucagon for
emergency use to treat hypoglycaemia. We collaborate with partners
to provide patients with effective treatments and quality
healthcare by ensuring we deliver accountability, partnership and
performance. For further information, please visit
www.tetrispharma.com.
Goodlife is a privately owned pharmaceutical
company with a focus on The Netherlands, Belgium and Luxembourg.
Goodlife believes that every patient deserves excellent care that
matches their individual needs, even if those needs deviate from
the norm. With this in mind, we strive for customization
every day, by providing unique medicines, medical devices, dietary
supplements and supportive tools for individual patients in the
BeNeLux. For more information, please visit www.goodlifepharma.com.
-ENDS-
For more
information, please contact:
Arecor Therapeutics plc
|
www.arecor.com
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email:
info@arecor.com
|
|
|
Susan Lowther, Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email:
info@arecor.com
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker)
|
|
Freddy Crossley, Emma Earl
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
|
WG
Partners LLP (Financial
Advisor)
|
|
Nigel Barnes, Satheesh
Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
ICR
Consilium
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email:
arecor@consilium-comms.com
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a
globally focused biopharmaceutical group transforming patient care
by bringing innovative medicines to market through the enhancement
of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are
developing an internal portfolio of proprietary products in
diabetes and other indications, as well as working with leading
pharmaceutical and biotechnology companies to deliver enhanced
formulations of their therapeutic products. The Arestat™ platform
is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com